Trials / Conditions / Hormone Receptor Positive Tumor

Hormone Receptor Positive Tumor

31 registered clinical trials studyying Hormone Receptor Positive Tumor — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of the TheraBionic P1 Device in Breast Cancer NCT07218432	Barbara Ann Karmanos Cancer Institute	N/A
Not Yet Recruiting	Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322	Regor Pharmaceuticals Inc.	Phase 1
Not Yet Recruiting	A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer NCT07227831	Barbara Ann Karmanos Cancer Institute	N/A
Recruiting	Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Met NCT06982521	Relay Therapeutics, Inc.	Phase 3
Recruiting	Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Ca NCT06650423	Institute of Oncology Ljubljana	—
Completed	First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors NCT05759949	Relay Therapeutics, Inc.	Phase 1
Recruiting	Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced C NCT05735080	Incyclix Bio	Phase 1 / Phase 2
Active Not Recruiting	Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer NCT05982093	SOLTI Breast Cancer Research Group	Phase 2
Recruiting	SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095	Fudan University	Phase 2
Recruiting	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499	Fudan University	Phase 2
Completed	Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/ NCT04352777	Duke University	Phase 2
Completed	Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastat NCT04134884	Kathy Miller	Phase 1
Unknown	Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer NCT04088110	Fuzhou General Hospital	Phase 2
Active Not Recruiting	Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer NCT03917082	British Columbia Cancer Agency	Phase 2
Unknown	Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC NCT03910712	Peking Union Medical College Hospital	Phase 2
Terminated	Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer NCT03874325	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) NCT03809988	MedSIR	Phase 2
Completed	Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) NCT04161833	Azienda Ospedaliero-Universitaria Careggi	N/A
Active Not Recruiting	Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer NCT03904173	Oslo University Hospital	—
Unknown	Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer NCT03691311	Institut Català d'Oncologia	EARLY_Phase 1
Completed	Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer NCT03407768	University of Saskatchewan	N/A
Completed	Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in F NCT03462251	iOMEDICO AG	Phase 3
Unknown	A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal NCT03906669	St Vincent's Hospital	Phase 2
Completed	Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer NCT03409198	Oslo University Hospital	Phase 2
Completed	Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant NCT02894398	iOMEDICO AG	Phase 2
Unknown	Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTO NCT02730923	Centre Leon Berard	Phase 1 / Phase 2
Unknown	Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer NCT02404051	Consorzio Oncotech	Phase 3
Active Not Recruiting	Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors NCT02592083	Thomas Hatschek	Phase 2
Completed	A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Ne NCT02441946	Eli Lilly and Company	Phase 2
Completed	Dose EScalation Induction of EvERolimus NCT02387099	GBG Forschungs GmbH	Phase 2
Recruiting	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379	QuantumLeap Healthcare Collaborative	Phase 2